he prevalence and morbidity of asthma are increasing and disproportionately affect innercity children. In the Second National Health and Nutritional Examination Survey, the prevalence of asthma was reported to be 3.0 percent among white children aged 6 months to 11 years and 7.2 percent in black children.' From 1979 to 1987, the hospitalization rate for children aged 0 through 17 years with asthma increased 4.5 percent per year. The hospitalization rate for black children aged 0 through 4 years was 1.8 times that of white children.2 Asthma is responsible for significant morbidity in children, including school absenteeism and the inability to participate in regular childhood activities. Asthma accounts for 25 percent of all school days missed among children with chronic medical conditions3 and, compared with the general school age population, asthmatics have a significantly higher absentee rate.4
Many inner-city children with asthma receive This study evaluated the efficacy of a simple intervention among pediatric patients with asthma receiving episodic care in a busy, urban ED. We hypothesized that providing a spacer device and a single, brief demonstration regarding its proper use would result in earlier resolution of asthma symptoms, a decrease in school absenteeism, and a decrease in the frequency of unscheduled medical visits and hospitalization for asthma.
METHODS

Study Population and Case Selection
The parents of children who presented to the Pediatric ED at the Bronx (NY) Municipal Hospital Center for the treatment of asthma between December 1, 1989 , and March 31, 1990, were interviewed to determine eligibility for the study.
To be eligible, a child had to be between the ages of 3 and 10 years, have a history of at least three asthma attacks after the age of 1 year, and his or her parent had to have access to a telephone for follow-up.
We excluded those children with chronic medical conditions other than asthma, children already using a spacer device or a home nebulizer, and children with any history of adverse effects from d-agonists.
Enrollment and Baseline Information
This study was an unblinded, prospective trial. Block randomization into one of two treatment groups by 1-week time periods was performed. In alternating 1-week intervals, children were assigned to a control group or an experimental group. At presentation and at discharge from the ED, the severity of each child's present asthma episode was scored using a pulmonary index score that measured respiratory rate, wheezing, L:E ratio, and accessory muscle use.°The range was from 0 (mild) to 12 (severe). At the time of discharge from the ED, the parents of those children who met all eligibility requirements and consented to participate, completed a baseline questionnaire. The questionnaire included demographic data and questions about the child's asthma history.
The control group received oral or inhaled 3-agonists according to the preference of the treating physician, but were not given a spacer device. Instead, they received a brief verbal reminder regarding the need to take their medications as prescribed as well as a printed sheet reemphasizing the same points. The spacer group received an inhaled f-agonist, a spacer device, and brief instructions in its use. Both groups were instructed to use their f-agonist four times per day for a 2-week period and then on an as-needed basis. If a parent perceived his or her child to require the fl-agonist more often than prescribed, they were asked to return to the ED for reevaluation. Patients in both groups were given additional asthma medications at the discretion of the evaluating physician.
Follow-up
Follow-up telephone questionnaires were completed at 1 week, and at 2, 4, and 6 months after enrollment and were used to assess the interval asthma history. Enrollment and follow-up interviews were completed by medical students or attending physicians who had no knowledge of whether the patient was in the control or spacer group. Parents reported on the average number of days of wheezing and coughing after the last asthma attack in that interval, the number of school days missed because of asthma, and the number of unscheduled medical visits and hospitalizations for asthma since the last contact. The data collected in each interval are not 
Statistical Analysis
To account for unequal variances in the groups, the Wilcoxon rank sum test was used to compare continuous variables. Categorical data were analyzed by the x2 test. Where the expected frequency in any cell was 5 or less, the Fisher exact test was used. Statistical significance was considered at p<O.05.
RESULTS
Ninety-eight patients were enrolled: 40 in the control group and 58 in the spacer group. No parents of eligible children refused to participate. Thirtythree patients (83 percent) in the control group and 51 (88 percent) in the spacer group completed the study. Seven patients were unavailable for follow-up from each group. Reasons for unavailability for follow-up were disconnected phones (three), no longer at their place of employment which was the only access to a telephone (one), change of residence with no forwarding information (one), "not at home" whenever the interviewer called (six), and no answer by telephone (three).
There were no significant differences between the spacer group and the control group on any baseline characteristics (Table 1) , including asthma severity score or the prescription of steroids at ED discharge. Table 2 presents the data on the median number of days of wheezing reported after an asthma attack in each of the follow-up intervals for the spacer and control groups. Children in the spacer group had significantly earlier resolution of wheezing at the 2-and 4-month follow up time points. There was no significant difference between the two groups at 1 week and 6 months. At the 2-and 4-month follow-up, children in the spacer group experienced significantly earlier resolution of coughing after an asthma attack than the control group (Table 3) . There was no significant difference in the two groups at 1 week or 6 months.
The median number of school days missed because of asthma was significantly less in the spacer group than in the control group at 2 and 4 months ( Table  4 ). There was no significant difference at 1 week or 6 months.
At the 2-, 4-, and 6-month follow-up time points, there were no significant differences in the number of unscheduled medical visits or hospitalizations, with both groups reporting similar low frequencies.
Since medications, including the spacer device, were used to lessen the severity of asthma symptoms and not as prophylaxis, we did not expect differences between the two groups in terms of the number of attacks. Instead, we reported on the physiologic and functional morbidity associated with asthma and not on the frequency of attacks. easily transferable to a health care facility serving an inner-city population with high volume and limited financial capability. In 1988, Howland et al14 reviewed the literature on pediatric asthma education. They found that when tests of statistical significance were applied to outcomes of educational programs, effectiveness in reducing morbidity, including school absenteeism and health care utilization, was small. Our study evaluated a brief intervention during an episodic ED visit for an acute asthma attack with limited intermittent follow-up. It was carried out at a site where disproportionate numbers of inner-city children receive their asthma care and it required minimal additional resources in an already stressed health care delivery system.
The literature concerning adults with asthma suggests that metered dose inhalers (MDIs) with spacers are as effective as nebulized therapy with beta agonists. A 1988 study by Morley et al15 showed that initial spirometry in hospitalized patients with asthma did not improve in the MDI with spacer group, while the nebulizer group showed significant inprovement. However, the mean rates of daily spirometric improvement were equal in both groups, as well as the mean length of hospitalization. Two studies on the use of MD1L with spacers > chiidicri wi-LI athrn'a have shown similar results. Karemn et al'6 found no significant differences in clinical outcome between patients treated with an MDI with spacer and those treated with a nebulizer. A second study by Benton et al17 evaluated the use of an MDI with a spacer in a pediatric ED and found improvement in peak flow, respiratory rate, and breath sounds although there was no comparison with a control or nebulizer group. A review of the English literature did not identify any studies concerning the use of MDIs with a spacer for home management of asthma in children.
Our study had some distinct limitations. All of our outcomes were based on parental report and we had no way of documenting the accuracy of these reports. However, many published surveys looking at the prevalence of wheezing in children have been based on parental report and these are accepted as credible accounts. Moreover, because all of our contact with patients after enrollment was by telephone, we do not know whether patients were using the device properly or, in fact, were continuing to use it at all, except as reported by parents. Telephone contact has been shown to be a successful strategy for follow-up'8 and we did not feel that on-site follow-up would be feasible in our population. In national surveys on access to care, it has been shown that people without telephones are more likely to have no The overall prevalence of symptoms was low at 6 months. Given these low frequencies, our sample was not large enough to enable us to detect differences between the groups. Thus, we were not able to study whether continued reinforcement would be necessary for continued adherence. The lack of a significant difference between the two groups at 6 months may be due to a seasonal decrease in asthma symptoms. Weiss19 has shown that hospitalizations for asthma for patients aged 5 to 34 years peaked in Septernber through November. All of our 6-month interval assessments were completed during or within 2 weeks of the summer months, prior to the start of the period of iricreased hospitalization rate.
In summary, the introduction of a spacer device during an emergency visit improved outcome in asthmatic children at 2 and 4 months after initiation in terms of the mean number of days of coughing and wheezing after an asthma attack, and the mean number of school days missed because of asthma.
Based on these data, we conclude that, despite the lack of opportunity for ongoing reinforcement and continuous personalized care, physicians caring for children with asthma in a busy, inner-city ED can prescribe a spacer device to enable young children to benefit from inhaled d-agonists and expect improvements in their symptoms and functional status.
